Companies will likely make submissions to Health Canada for approval of gene therapies for hemophilia A and B in the next 6-12 months. To best represent people with hemophilia with regulators, health technology assessment bodies and provincial/territorial governments, the CHS needs patient input. If you …
… please complete this 12-question survey regarding gene therapy.
Answers are completely anonymous. Thank you for providing your valuable input to the CHS and thank you for sharing this invitation with your chapter members. The survey will close on September 1, 2022.
CLICK HERE to take the survey.